Prime Medicine (PRME) Income from Continuing Operations (2021 - 2026)
Prime Medicine posted quarterly Income from Continuing Operations of 49633000.0 for Q1 2026, up 4.35% year-on-year from 47564156.28 in Q1 2025, and down 4.44% on a QoQ basis from 47525000.0 in Q4 2025.
Prime Medicine (PRME) has 6 years of Income from Continuing Operations data on file, last reported at 49633000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 4.35% year-over-year to 49633000.0; the trailing twelve-month figure through Mar 2026 stood at 202581000.0 (changed 0.28% YoY), and the FY2025 full-year result was 204201000.0, down 4.25% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 49633000.0, down from 47525000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 23840000.0 in Q1 2022 and bottomed at 65643000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 47525000.0 (2025), against an average of 45312176.47.
- Peak annual rise in Income from Continuing Operations reached 37.54% in 2022, while the deepest fall reached 78.83% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 39283000.0 in 2022, then sank by 67.1% to 65643000.0 in 2023, then jumped by 35.6% to 42276000.0 in 2024, then dropped by 12.42% to 47525000.0 in 2025, then retreated by 4.44% to 49633000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 49633000.0 (Q1 2026), 47525000.0 (Q4 2025), and 52832000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - | -49.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.63 Mn |
| Dec 31, 2025 | -47.53 Mn |
| Sep 30, 2025 | -52.83 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.89 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.33 Mn |
| Mar 31, 2024 | -45.76 Mn |
| Dec 31, 2023 | -65.64 Mn |
| Sep 30, 2023 | -50.71 Mn |
| Jun 30, 2023 | -42.39 Mn |
| Mar 31, 2023 | -39.40 Mn |
| Dec 31, 2022 | -39.28 Mn |
| Sep 30, 2022 | -29.35 Mn |
| Jun 30, 2022 | -29.35 Mn |
| Mar 31, 2022 | -23.84 Mn |
| Dec 31, 2021 | -62.90 Mn |
| Sep 30, 2021 | -16.41 Mn |